Pioneering a new kind of treatment

Orphazyme is pioneering the development of a new type of medical treatment by applying our specialized expertise in heat shock proteins—a key component of the body’s natural cellular stress-defense system.

By leveraging the potential of heat shock proteins, such as heat shock protein 70 (HSP70), we are advancing treatments for patients living with a range of neurodegenerative orphan diseases. These diseases can have a devastating impact, and the lack of existing approved treatment options leaves a substantial gap in care today.

 

LEARN MORE

NEWS HIGHLIGHTS

Orphazyme announces topline data from pivotal trial of arimoclomol in Amyotrophic Lateral Sclerosis (ALS)

Orphazyme A/S Company announcement No. 14/2021 Inside information Company Registration No. 32266355 Pivotal trial did not meet primary and secondary endpoints evaluating impact on function and survival Orphazyme remains focused on commercial readiness and potential U.S.

VIEW ALL NEWS